Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2001-02-28
2002-01-08
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S212000, C435S219000, C424S489000
Reexamination Certificate
active
06337069
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to methods of treating inflammation associated with rhinitis or sinusitis by intranasally delivering peptidases to a patient. The invention also encompasses therapeutic packages in which a peptidase is preloaded in a device designed for intranasally delivering drug.
BACKGROUND OF THE INVENTION
Rhinitis, an inflammation of the nasal mucosal membrane, is characterized by sneezing, rhinorrhea, nasal congestion, and increased nasal secretion. It is often accompanied by sinusitis, an inflammation of the sinuses. When these conditions persist for a period of more than three weeks, they are termed “chronic.” More than 37 million Americans, particularly those with allergies or asthma, suffer from these conditions, making them the most common chronic medical problems in the United States.
Chronic “rhinosinusitis” or sinusitis is difficult to treat successfully. In general, treatment consists of a combination of antibiotics and decongestants or antihistamines. In addition, steroid nasal sprays are commonly used to reduce inflammation. For patients with severe chronic sinusitis, oral steroids, such as prednisone, may also be prescribed. However, the long-term safety of steroid administration, especially in children, is not fully understood and oral steroids often have significant side effects. When drug therapy fails, surgery is usually the only alternative.
The mucosal tissue lining the nasal and sinus passages is densely packed with sensory neurons (Alving, et al.,
Cell Tissue Res.
264:529-538 (1991); Saria, et al.,
Am. Rev. Respir. Dis.
147:1330-1335 (1988)). When activated, these neurons release a variety of bioactive peptides that contribute to inflammation by causing vasodilation, stimulating mucosal gland secretion, and promoting infiltration by inflammatory mast cells, lymphocytes and eosinophils (Stead, et al,
Immunol. Rev.
10:333-359 (1987); Mygind, et al.,
Eur. J Respir. Dis.
64(S128):1-379 (1983)). Included among the released bioactive peptides are substance P, calcitonin-gene related peptide, neuropeptide Y and vasoactive intestinal peptide (Lundblad, et al.,
Acta. Physiol. Scand.
529:1-42 (1984)). Means for controlling the activity of these peptides should provide an effective treatment for the inflammation associated with both rhinitis and sinusitis.
SUMMARY OF THE INVENTION
The present invention stems from the discovery that dipeptidyl peptidase IV, an exopeptidase that cleaves Xaa-Pro dipeptides from the N-terminus of polypeptides, is present in human nasal mucosa at levels that are inversely related to inflammation. Thus, low levels of dipeptidyl peptidase IV are associated with a high density of inflammatory cells, and high levels of dipeptidyl peptidase IV are associated with a low density of inflammatory cells. This is important because dipeptidyl peptidase IV degrades peptides that contribute to the pathophysiology of rhinitis, sinusitis and asthma (Mentlein, et al.,
Regul. Peptides
49:133-144 (1993); Heymann, et al,
FEBS Lett.
91:360-364 (1978); Beauvais, et al.,
Fum. Infect. Immun.
65:3042-3047 (1997)). Among the inflammation-related peptides cleaved are NPY, SP, and desArg1 bradykinin. Based upon these observation and further experiments, the concept has been developed that the intranasal administration of dipeptidyl peptidase IV can reduce inflammation in the mucosal tissue that lines both the nasal cavity and sinuses. Other proteases that possess the same proteolytic activity should also produce a positive therapeutic effect. These proteases include quiescent cell proline dipeptidase (Underwood, et al.,
J. Biol. Chem.
274:34053-34058 (1999)), dipeptidyl peptidase 8 (Abbott, et al.,
Eur. J Biochem.
267:6140-6150 (2000)), and attractin (Duke-Cohan, et al.,
Proc. Nat'l. Acad. Sci. U.S.A.
95:11336-11341 (1998)).
In its first aspect, the invention is directed to a method of treating a patient for inflammation of the nasal or sinus mucosa. The method involves intranasally administering a therapeutically effective amount of a peptidase (preferably an exopeptidase) that cleaves at Xaa-Pro residues, where Xaa represents any of the 20 amino acids commonly found in animals. A “therapeutically effective” dose is defined as an amount sufficient to produce a significant reduction in inflammation as evidence by either a reduced number of inflammatory cells in mucosal tissue or by a significant improvement in one or more symptoms associated with the inflammation. For example, in the case of rhinitis or sinusitis, a therapeutically effective dose would be a sufficient amount to produce a significant reduction in sneezing, coughing, sinus-related headaches, nasal obstruction, mucosal secretion, or other discomfort associated with these conditions. Inflammatory cells include mast cells, lymphocytes and eosinophils. In general, it is expected that a therapeutically effective dose for any of the proteases used will be between 1 microgram and 1 milligram and, typically, between 5 micrograms and 500 micrograms.
The preferred peptidase for use in the method is dipeptidyl peptidase IV. Other peptidases that can be used include quiescent cell proline dipeptidase; dipeptidyl peptidase 8, and attractin. In each case, it is the human form of the peptidase that is preferred. However, peptidases from other species (e.g., that secreted by
Aspergilus Fumigatus,
see Examples section) may also be used provided that they have the ability to cleave at the Xaa-Pro sequence. Although the method will work for rhinitis and sinusitis caused by any disease or condition, it is expected that the most common causes will be allergies or asthma.
In another aspect, the invention is directed to a therapeutic package in which a device for intranasally delivering drug to a patient is preloaded with a solution or powder containing one or more of the peptidases described above. The invention is compatible with any intranasal delivery device (including encapsulated dosage forms) and with any of the numerous compositions that have been described for delivering drugs by means of the nasal cavity. When liquid compositions are used in the device, it is expected that peptidase will be present at a concentration of between 1 &mgr;g/ml and 10 mg/ml, and more typically, at a concentration of between 10 &mgr;g/ml. and 1 mg/ml.
The invention also encompasses the concept that SP is particularly important in causing inflammation in lung and nasal mucosa. Any method that reduces the local activity of this peptide should be useful in the treatment of rhinitis or sinusitis. A reduction in activity may be accomplished either using a peptidase that degrades SP (e.g., one of the peptidases described above) or by administering an agent that inhibits the binding of SP to the NK1 receptor (see Examples section).
DETAILED DESCRIPTION OF THE INVENTION
A. Preparation of Peptidases
The present invention is directed to treatment methods which utilize peptidases that have the common characteristic of cleaving at Xaa-Pro sites. These may be purchased commercially or obtained using any of the procedures described in the relevant literature. For example, the gene corresponding to the peptidase can be isolated and used for recombinant protein production. Especially preferred peptidases, along with references relevant to their isolation and recombinant production, are: human dipeptidyl peptidase IV, shown herein as SEQ ID NO: 1 (Misumi, et al,
Biochim. Biophys. Acta
15:1131 (1992); Darmoul, et al.,
J. Biol. Chem.
267:4824-4833 (1992); Abbott, et al.,
Immunogenetics
40:331-338 (1994)); human quiescent cell proline dipeptidase, shown herein as SEQ ID NO: 2 (Underwood, et al,
J. Biol. Chem.
274:34053-34058 (1999)); human attractin, shown herein as SEQ ID NO: 3 (Duke-Cohan, et al.,
Proc. Nat'l. Acad. Sci. USA
95:11336-11341 (1998); Nagase, et al,
DNA Res.
5:31-39 (1998)); and human dipeptidyl peptidase 8, shown herein as SEQ ID NO: 4 (Abbott, et al.,
Eur. J. Biochem.
267:6140-6150 (2000)). In addition to being made recombinantly, these proteins c
Grouzmann Eric
Lacroix Jean-Silvain
Monod Michel
B.M.R.A. Corporation B.V.
Meller Mike
Naff David M.
Pillsbury & Winthrop LLP
Sanzo Michael A.
LandOfFree
Method of treating rhinitis or sinusitis by intranasally... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating rhinitis or sinusitis by intranasally..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating rhinitis or sinusitis by intranasally... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2828405